^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

ALK negative

i
Other names: NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor
Entrez ID:
3d
Fine-needle aspiration cytology of Hodgkin-like ALK-negative anaplastic large cell lymphoma: Cytomorphological clues and the diagnostic value of subtle background cell atypia. (PubMed, J Clin Exp Hematop)
Careful assessment of nuclear morphology and cell distribution patterns can provide valuable diagnostic clues to prevent misdiagnosis. This rare cytological presentation offers critical educational insights for cytopathologists and underscores the diagnostic value of FNA cytology, particularly when integrated with immunophenotypic analysis and retrospective morphological review in evaluating morphologically challenging lymphoid malignancies.
Journal
|
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8) • PAX5 (Paired Box 5) • IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • GZMB (Granzyme B) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
|
ALK negative
7d
Long-term survival in a patient with leptomeningeal metastases from non-small cell lung cancer treated with stereotactic radiotherapy (SRT), programmed cell death protein 1 (PD-1) inhibitor, and granulocyte-macrophage colony-stimulating factor (GM-CSF): a case report. (PubMed, Transl Cancer Res)
In this case, however, the patient achieved a remarkable PFS of over 4 years following a multimodal regimen combining SRT, PD-1 inhibition, and GM-CSF. This tri-modality strategy emerges as a promising therapeutic paradigm for NSCLC-associated LM.
Journal
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • CSF2 (Colony stimulating factor 2)
|
ALK negative
8d
Rapidly Growing ALK-Negative NTRK3-Positive Inflammatory Myofibroblastic Tumour of the Lung. (PubMed, Respirol Case Rep)
The patient remains disease-free at 9 months postoperatively. This case highlights the importance of comprehensive molecular testing in ALK-negative IMT and demonstrates that complete surgical resection can achieve excellent outcomes even in rapidly growing lesions.
Journal
|
ALK (Anaplastic lymphoma kinase) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6)
|
ALK positive • ALK negative • NTRK positive
8d
Trial completion date
|
ALK (Anaplastic lymphoma kinase) • CD8 (cluster of differentiation 8)
|
ALK positive • ALK negative
|
Ezharmia (valemetostat)
10d
Primary ALK-Negative Anaplastic Large Cell Lymphoma Mimicking Septic Arthritis in a Diabetic Patient: Diagnostic and Therapeutic Challenges. (PubMed, J Vis Exp)
A carefully staged treatment plan was employed, beginning with corticosteroids and etoposide, followed by liposomal mitoxantrone and the CD30-targeted antibody-drug conjugate brentuximab vedotin. The clinical course highlights the necessity of maintaining a high index of suspicion for lymphoma in refractory joint infections and demonstrates that individualized, stepwise therapy can achieve remission even in critically ill patients with aggressive ALCL. These findings provide valuable insights for improving the diagnosis and management of lymphoma cases that mimic infectious diseases.
Journal
|
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
ALK negative
|
etoposide IV • Adcetris (brentuximab vedotin) • Duoenda (mitoxantrone liposomal)
15d
PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma (clinicaltrials.gov)
P1, N=12, Terminated, Henan Cancer Hospital | Phase classification: P1/2 --> P1 | Trial completion date: Feb 2025 --> Aug 2025
Phase classification • Trial completion date
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive • ALK negative
|
Epidaza (chidamide) • parsaclisib (INCB50465)
28d
Clinicopathological Features and Immunochemical Staining of Inflammatory Myofibroblastic Tumor: A Retrospective Study of 48 Cases. (PubMed, Anal Cell Pathol (Amst))
For desmin and cytokeratin, the results differed among cases and may not be used as determinant factors to diagnose such diseases. We hope that this investigation will be a cornerstone for further studies on the diagnosis of IMT in the absence of ALK rearrangements.
Retrospective data • Journal
|
ALK (Anaplastic lymphoma kinase) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD34 (CD34 molecule) • ANO1 (Anoctamin 1)
|
ALK positive • ALK rearrangement • ALK negative
1m
Anaplastic large cell lymphoma in the penis: a case report and review of literature. (PubMed, J Med Case Rep)
This case highlights the diagnostic challenge posed by rare penile lesions and, more importantly, the therapeutic dilemma of selecting an appropriate treatment for a disease that is localized yet multifocal. The successful outcome with systemic brentuximab vedotin plus cyclophosphamide, doxorubicin, vincristine, and prednisone therapy, a deviation from standard guidelines for unifocal primary cutaneous anaplastic large cell lymphoma, underscores the need for individualized treatment strategies and further research to establish risk-adapted guidelines for this rare clinical entity.
Review • Journal
|
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 expression • ALK negative
|
doxorubicin hydrochloride • cyclophosphamide • Adcetris (brentuximab vedotin) • vincristine • prednisone
1m
Trial completion
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • PTEN (Phosphatase and tensin homolog) • PI3K (Phosphoinositide 3-kinases)
|
ALK rearrangement • EGFR wild-type • KRAS wild-type • RAS wild-type • ALK negative
|
docetaxel • Tyvyt (sintilimab) • albumin-bound paclitaxel • afuresertib (LAE002)
1m
Anaplastic lymphoma kinase-negative inflammatory myofibroblastic tumor of the appendix and ileocecal region: a rare clinical entity. (PubMed, J Surg Case Rep)
Surgical resection remains the mainstay of treatment. This case highlights the importance of including IMT in the differential diagnosis of atypical intra-abdominal masses and supports the role of advanced molecular techniques in improving diagnostic accuracy and management.
Journal
|
ALK (Anaplastic lymphoma kinase)
|
ALK negative
1m
ALK-Negative Anaplastic Large Cell Lymphoma With Rare Scalp Involvement: A Case Report and Literature Review. (PubMed, J Investig Med High Impact Case Rep)
Histopathological analysis confirmed lymphoma with atypical large cells, and immunohistochemistry showed that both ALK and CD30 were negative, making the diagnosis atypical. This case illustrates the rarity of scalp involvement in ALK-negative ALCL and underscores the importance of a multidisciplinary approach, integrating clinical, imaging, and histological findings for accurate diagnosis and management.
Journal
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
ALK negative
1m
P30CA033572: Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma (clinicaltrials.gov)
P2, N=48, Active, not recruiting, City of Hope Medical Center | Trial completion date: Aug 2025 --> Jul 2026
Trial completion date
|
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
ALK positive • TNFRSF8 positive • ALK negative
|
doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • daunorubicin